Yukiko Mogami

Dr. Yukiko Mogami

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in Epilepsy Research
Verified
Journal Article
Closed access
YTYukkitoshi Takahashi
Yukkitoshi Takahashi
YMYukiko Mogami
Yukiko Mogami
JMJune Mine
June Mine
KIKatsumi Imai
Katsumi Imai
YKYasumichi Koide
Yasumichi Koide
YIYushi Inoue
Yushi Inoue

23 July 2025 in Life
Verified
Journal Article
Open access
PDF file
YAYuichi Abe
Yuichi Abe
THToshimitsu Hamasaki
Toshimitsu Hamasaki
JNJun Natsume
Jun Natsume
YMYukiko Mogami
Yukiko Mogami
KMKei Murayama
Kei Murayama
AOAkira Ohtake
Akira Ohtake
An explorative study was conducted to evaluate the efficacy and safety of 5-aminolevulinic acid hydrochloride combined with sodium ferrous citrate (SPP-004) in 10 pediatric patients with Leigh syndrome (LS) aged 3–24 months in 10 institutions between December 2014 and July 2019. The patients were randomized and allocated to the SPP-004 or placebo group for a 12-week double-blind period, followed by a 12-week open-label period with SPP-004 and then a long-term study of up to 180 weeks. The efficacy and safety were evaluated using the Newcastle Pediatric Mitochondrial Disease Scale (NPMDS) and adverse events (AEs), respectively. No significant differences were found between groups in NPMDS scores, but prolonged SPP-004 treatment stabilized or improved scores. During the initial double-blind phase, the serum lactate levels increased in the placebo group but not in the SPP-004 group. Over the period of prolonged treatment with SPP-004, the average serum lactate level gradually decreased to a normal level. One patient died due to heart failure, presumably due to an underlying disease. Overall, 7 out of 10 patients received SPP-004 without developing severe AEs until the termination of the long-term study. Given the severe symptoms and poor prognosis of pediatric LS, NPMDS scores were indicative of stabilization in pediatric LS patients treated with SPP-004.

1 June 2018 in Journal of Cardiology Cases
Verified
Journal Article
Closed access
SFShutaro Futami
Shutaro Futami
JIJoji Ishikawa
Joji Ishikawa
YAYukari Arima
Yukari Arima
YMYukiko Mogami
Yukiko Mogami
YNYoshiko Nemoto
Yoshiko Nemoto
KHKazumasa Harada
Kazumasa Harada

21 July 2015 in Child Neurology Open
Verified
Journal Article
Open access
TKTomokazu Kimizu
Tomokazu Kimizu
HTHiromitsu Toshikawa
Hiromitsu Toshikawa
SKSadami Kimura
Sadami Kimura
TITae Ikeda
Tae Ikeda
YMYukiko Mogami
Yukiko Mogami
YSYasuhiro Suzuki
Yasuhiro Suzuki
Ictal bradycardia, which is considered to be one of the causes of sudden unexplained death in epilepsy, is rare. A 10-year-old girl with focal cortical dysplasia in her right centroparietal region developed transient ictal bradycardia during cluster seizures. Brain magnetic resonance imaging demonstrated a high signal intensity lesion adjacent to the focal cortical dysplasia lesion. Ictal 99mTc-ethyl cysteinate dimer single-photon emission computed tomography (SPECT) detected hyperperfusion in an area containing the high signal intensity lesion, which was located close to the insular cortex. Since the hyperperfusion zone observed on SPECT was considered to reflect seizure propagation, it is possible that the ictal bradycardia experienced in the present case was caused by the following mechanism: The repetitive seizure activity caused the high-intensity lesion seen on MRI to expand into the right insular cortex, which controls cardiac rhythm, resulting in ictal bradycardia.